Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Dose Escalation Study to Assess the Safety and Tolerability of IMM01-STEM in Participants With Muscle Atrophy Related to Knee Osteoarthritis

Next Previous
Trial Profile

An Open-label Dose Escalation Study to Assess the Safety and Tolerability of IMM01-STEM in Participants With Muscle Atrophy Related to Knee Osteoarthritis

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMMUNA (Primary)
  • Indications Muscular atrophy; Sarcopenia
  • Focus Adverse reactions; First in man
  • Sponsors Immunis

Most Recent Events

  • 01 Jul 2025 Number of treatment arms increased from 3 to 4 by the addition of Cohort D, IMM01-STEM 2000 microgram. Inclusion criteria is updated to remove the criteria of "negative lab test results for HIV, HBsAg, HCV".
  • 01 Jul 2025 Planned number of patients changed from 18 to 28.
  • 01 Jul 2025 Planned End Date changed from 15 Jan 2025 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top